- Home
- PTGX vs MAC Comparison
PTGX vs MAC Comparison
Compare PTGX & MAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | MAC |
|---|---|---|
| Founded | 2006 | 1964 |
| Country | United States | United States |
| Employees | N/A | 2845 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.3B |
| IPO Year | 2016 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PTGX | MAC |
|---|---|---|
| Price | $121.88 | $25.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $108.23 | $20.50 |
| AVG Volume (30 Days) | 705.9K | ★ 3.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | N/A | ★ 11.36 |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $1,013,983,000.00 |
| Revenue This Year | $874.25 | N/A |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | $2,455.60 | ★ N/A |
| Revenue Growth | N/A | ★ 10.43 |
| 52 Week Low | $49.86 | $15.94 |
| 52 Week High | $126.25 | $25.80 |
Technical Indicators
Market Signals| Indicator | PTGX | MAC |
|---|---|---|
| Relative Strength Index (RSI) | 66.64 | 67.57 |
| Support Level | $94.48 | $17.84 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 4.67 | 0.71 |
| MACD | 1.54 | 0.11 |
| Stochastic Oscillator | 77.87 | 96.30 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
About MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and seven other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $867 sales per square foot over the 12 months ended in September 2025.